Quantitative Analysis of Cell-Based Luciferase Fusion Reporters


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Cell-based reporters expressing luciferase fusions with transcription factors or their protein stability domains can be considered as microbioreactors providing a way to directly monitor the stability of the luciferase labeled transcription factor or its domain in real-time. To understand principal advantages and/or limitations of these systems for the purposes of applied and fundamental research one needs to develop a quantitative description of their performance based on the determination of actual intracellular concentrations of the fusion proteins and rates of their production. In this work, the experimental data generated by means of luciferase activity calibration were used to calculate the steady-state intracellular concentrations of luciferase fusions in SH-SY5Y neuroblastoma cell lines stably expressing HIF1 ODD-luc and Neh2-luc proteins. For both reporters, the concentration of fusion proteins was determined as 60–80 nM, the values close to those for Michaelis constants for HIF prolyl hydroxylase (10–100 nM HIF) and the dissociation constant for Keap1-Nrf2 complex (50 nM), the parameters controlling rate-limiting steps of HIF1 ODD-luc and Neh2-luc reporter performance, respectively. New data allowed us to calculate the production rates and maximum concentrations for the fusion proteins under the conditions of irreversible activation and protein stabilization. The quantitative analysis of the Neh2-luc reporter performance employing the newly generated parameters explains the multi-order shift in the apparent activation constant versus the “real” dissociation constant determined for a known Nrf2 displacement activator using fluorescent polarization homogeneous assay with recombinant Keap1 and labeled Nrf2 peptide.

About the authors

A. Yu. Khristichenko

D. Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
of Healtcare Ministry of Russia

Email: vitishkov@gmail.com
Russian Federation, Moscow, 117997

A. A. Poloznikov

D. Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
of Healtcare Ministry of Russia

Email: vitishkov@gmail.com
Russian Federation, Moscow, 117997

D. M. Hushpulian

D. Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
of Healtcare Ministry of Russia

Email: vitishkov@gmail.com
Russian Federation, Moscow, 117997

N. A. Smirnova

D. Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
of Healtcare Ministry of Russia

Email: vitishkov@gmail.com
Russian Federation, Moscow, 117997

A. A. Zakhariants

Innovations and High Technologies MSU Ltd

Email: vitishkov@gmail.com
Russian Federation, Moscow, 109559

S. V. Kazakov

Department of Chemistry and Physical Sciences, Dyson College, Pace University, Pleasantville

Email: vitishkov@gmail.com
United States, NY, 10570

V.I. Tishkov

Innovations and High Technologies MSU Ltd; Moscow State University, Department of Chemistry; A.N. Bach Institute of Biochemistry, Federal Research Centre “Fundamentals of Biotechnology”
of the Russian Academy of Sciences

Author for correspondence.
Email: vitishkov@gmail.com
Russian Federation, Moscow, 109559; Moscow, 119991; Moscow, 119071

I. G. Gazaryan

D. Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
of Healtcare Ministry of Russia; Innovations and High Technologies MSU Ltd; Moscow State University, Department of Chemistry

Email: vitishkov@gmail.com
Russian Federation, Moscow, 117997; Moscow, 109559; Moscow, 119991

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Allerton Press, Inc.